NOMAC : New Tools for Managing the Fate of Cereal Nutrients in the Gut : Effects of Amylose Content on Glycemic Index.

NCT ID: NCT01437917

Last Updated: 2012-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The consumption of cereals-based foods with low glycemic indexes, high micronutrients and fibers contents are highly recommended. The target of this work is to provide new solutions for cereal based foods: the knowledge and understanding on the in vivo fate will be used to define structural features to gain in foods.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bread with 20% amylose content

Bread with 20% amylose content

Group Type EXPERIMENTAL

20% amylose bread

Intervention Type OTHER

20% amylose bread

Bread with 10% amylose content

Bread with 10% amylose content

Group Type EXPERIMENTAL

10% amylose bread

Intervention Type DIETARY_SUPPLEMENT

10% amylose bread

carbohydrates

50g of carbohydrates ingested with 400 ml of water

Group Type EXPERIMENTAL

Carbohydrates

Intervention Type DIETARY_SUPPLEMENT

50g of carbohydrates ingested with 400 ml of water

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

20% amylose bread

20% amylose bread

Intervention Type OTHER

10% amylose bread

10% amylose bread

Intervention Type DIETARY_SUPPLEMENT

Carbohydrates

50g of carbohydrates ingested with 400 ml of water

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy individual,
* Age between 19-65 years
* With normal food habits with at least 2 main meals per day
* Non smoking
* Having filled the consent form

Exclusion Criteria

* BMI \> 25 kg/m2,
* Diabetes or any illness susceptible to alter
* Coeliac disease
* Past history of intestinal diseases.
* Treatment susceptible of modifying glycemia.
* Allergy
Minimum Eligible Age

19 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

OTHER

Sponsor Role collaborator

Rennes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fabrice BONNET, MD

Role: PRINCIPAL_INVESTIGATOR

Rennes University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rennes University Hospital

Rennes, Brittany Region, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-A00517-34

Identifier Type: OTHER

Identifier Source: secondary_id

11/19-808

Identifier Type: OTHER

Identifier Source: secondary_id

B110607-50

Identifier Type: OTHER

Identifier Source: secondary_id

LOC/11-05 - NOMAC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Glycaemic Response Testing
NCT01536847 COMPLETED NA
Glycemic Index and Brain Function
NCT01064778 COMPLETED NA